Last reviewed · How we verify

H001 Capsule 200mg-qd — Competitive Intelligence Brief

H001 Capsule 200mg-qd (H001 Capsule 200mg-qd) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor. Area: Cardiovascular.

phase 2 ACE inhibitor Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

H001 Capsule 200mg-qd (H001 Capsule 200mg-qd) — Livzon Pharmaceutical Group Inc.. H001 Capsule 200mg-qd is a medication that targets the renin-angiotensin system to lower blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
H001 Capsule 200mg-qd TARGET H001 Capsule 200mg-qd Livzon Pharmaceutical Group Inc. phase 2 ACE inhibitor Angiotensin-converting enzyme (ACE)
Vasotec enalapril Merck & Co. marketed ACE inhibitor Angiotensin-converting enzyme, Angiotensin-converting enzyme 1985-12-24
Lotrel (amlodipine/benazepril) Lotrel (amlodipine/benazepril) Abbott marketed Calcium channel blocker / ACE inhibitor combination L-type calcium channels (amlodipine); Angiotensin-converting enzyme (benazepril)
Perindopril plus Hydrochlorothiazide Perindopril plus Hydrochlorothiazide University of Abuja marketed ACE inhibitor plus thiazide diuretic combination Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter in the distal convoluted tubule
Calcium Channel Blockers, ACE-Inhibitor Calcium Channel Blockers, ACE-Inhibitor University of Aarhus marketed Combination antihypertensive (calcium channel blocker + ACE inhibitor) L-type calcium channels; Angiotensin-converting enzyme (ACE)
trandolapril/verapamil trandolapril/verapamil Abbott marketed ACE inhibitor / calcium channel blocker combination Angiotensin-converting enzyme (ACE); L-type voltage-gated calcium channels
Perindopril + amlodipine + if necessary, hydrochlorothiazide Perindopril + amlodipine + if necessary, hydrochlorothiazide Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company marketed ACE inhibitor + calcium channel blocker + thiazide diuretic combination Angiotensin-converting enzyme (ACE), L-type calcium channels, sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor class)

  1. Boryung Pharmaceutical Co., Ltd · 5 drugs in this class
  2. Bioprojet · 2 drugs in this class
  3. Ain Shams University · 2 drugs in this class
  4. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
  5. Beijing Tide Pharmaceutical Co., Ltd · 1 drug in this class
  6. Children's Hospital of Fudan University · 1 drug in this class
  7. Ache Laboratorios Farmaceuticos S.A. · 1 drug in this class
  8. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
  9. Ethicare GmbH · 1 drug in this class
  10. Ace Cells Lab Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). H001 Capsule 200mg-qd — Competitive Intelligence Brief. https://druglandscape.com/ci/h001-capsule-200mg-qd. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: